Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248404 · ClinicalTrials.gov registry record · Phase 1
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
A Phase 1 study of Tumors, sponsored by Kiadis Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 155
- Enrollment target
- 3
- Study locations
NCT00248404 is a Phase 1 study of Tumors that has completed, run by Kiadis Pharma. The registered enrollment target is 155 participants, below the 192-participant average among 20 other Tumors trials with a reported enrollment target (19% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00248404, a Phase 1 study of Tumors, has completed, sponsored by Kiadis Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 155 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
Conditions Studied
Interventions
- DRUG NB1011
Study Locations (3)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
Minnesota
- University of Minnesota - Minneapolis
Ontario
- Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00248404
The ClinicalTrials.gov registry entry for NCT00248404 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 20 other Tumors trials with a reported enrollment target (19% lower). The listed sponsor is Kiadis Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which NB1011 is the first listed.
NCT00248404 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Minnesota, Ontario.
Frequently Asked Questions
What is clinical trial NCT00248404 about?
NCT00248404 is a clinical study titled "NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)". The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
What is the current status of trial NCT00248404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2005-09. Estimated completion is 2007-12-12.
What conditions does trial NCT00248404 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT00248404?
The interventions under investigation include: NB1011 (DRUG).
Who is sponsoring clinical trial NCT00248404?
This trial is sponsored by Kiadis Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00248404 being conducted?
This trial has 3 study locations across California, Minnesota, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.